Increased risk of adverse pregnancy outcomes in HIV-infected women treated with highly active antiretroviral therapy in Europe.
Highly active antiretroviral therapy (HAART) may be associated with adverse pregnancy outcomes. Among 4372 live births in the European Collaborative Study, the prematurity rate increased to 24.9% in 2000-2004. Antenatal HAART use initiated pre-pregnancy was strongly associated with prematurity (AOR 2.05, 95% CI 1.43, 2.95), particularly severe prematurity. The implication of increased prematurity is evidenced in high neonatal mortality in these groups (0.66% for infants at 34-36 weeks and 7.37% at < 34 weeks' gestation).
Thorne
Claire
C
Centre for Paediatric Epidemiology and Biostatistics, Institute of Child Health, University College London, London, UK.
Patel
Deven
D
Newell
Marie-Louise
ML
D000293:Adolescent; D000328:Adult; D023241:Antiretroviral Therapy, Highly Active / Q000379:methods*; D002648:Child; D005260:Female; D005865:Gestational Age; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D007226:Infant Mortality; D007230:Infant, Low Birth Weight; D007231:Infant, Newborn; D007234:Infant, Premature; D008875:Middle Aged; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000188:drug therapy*; D011295:Prenatal Care / Q000379:methods; D012307:Risk Factors